Caplight Directory>Companies>GCTx-preview>Gc-therapeutics


GCTx

GCTx

Private
Cambridge, MassachusettsHealthcare & Life Scienceswww.gc-tx.com

Last Round

Series A

Sep 19, 2024

Total Funding Raised

$75M

Company Overview

GC Therapeutics is a biotechnology company that specializes in programming patient-derived stem cells into various cell types using an innovative platform that combines synthetic biology and artificial intelligence to create advanced cell therapies with enhanced manufacturing efficiency and quality.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Infrastructure

Keywords

cell therapyinduced pluripotent stem cellsiPSCsoff-the-shelf cell therapyallogeneic cell therapyTFome platformcell programmingsynthetic biologycell engineeringgene editingiPSC programmingtranscription factorsregenerative medicineAI drug discoveryprogrammable medicinegastrointestinal therapyneurological therapyimmunology therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

GCTx Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

GCTx Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series ASep 19, 2024
View all Funding Rounds

Key People

Founding team and executive leadership

Maura McInerney

CFO Consultant

Executive Team

GCTx Investors

Notable investors and investment history

InvestorRounds
Andreessen HorowitzSeries A
Medical Excellence CapitalSeries A
Pear VCSeries A
Mubadala CapitalSeries A
Cercano ManagementSeries A
Mubadala Investment CompanySeries A
Cormorant Asset ManagementSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 9, 2026

    Kate Haviland appointed as new board chair.

  • Apr 1, 2025

    Proprietary TFome™ platform developed in Professor George Church's lab.

View all signals

GCTx Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

GCTx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about GCTx's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range43
Year Founded2019
Last FundingSep 19, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.